Ann: Kyocera completes Progenza Due Diligence, page-8

Thanks @ma420

When it comes to Covid, I'm extremely cautious.
Tying up a product delivery to such a topical matter would most certainly create disappointments, such as results not as good as hoped for, clinical delivery more complicated than anticipated, or even other solutions superceeding this one.

I look at MSB: they are a few years ahead of RGS, obviously, and their accelerated clinical study for Covid is not without risks (of the same nature as mentioned above).

However, longer term, RGS's platform has my preference compared to MSB's beacuse it includes secretions of Mesenchymal Stem Cells. If RGS uses some of Kyocera money to fund clinical studies around respiratory inflammations it will forge the way to commecialising their products ahead of the next pandemic.
They could prove me wrong, if studies are on the way, and Covid is still here in 18/24 months